Research Analysts Offer Predictions for ADCT Q1 Earnings

ADC Therapeutics SA (NYSE:ADCT) – Equities researchers at HC Wainwright boosted their Q1 2025 earnings estimates for shares of ADC Therapeutics in a note issued to investors on Monday, March 31st. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.39) for the quarter, up from their previous estimate of ($0.41). HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for ADC Therapeutics’ current full-year earnings is ($1.69) per share. HC Wainwright also issued estimates for ADC Therapeutics’ Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.42) EPS and FY2025 earnings at ($1.62) EPS.

ADCT has been the subject of several other reports. Stephens increased their price target on ADC Therapeutics from $6.00 to $8.00 and gave the stock an “overweight” rating in a report on Monday, February 24th. Cantor Fitzgerald restated an “overweight” rating on shares of ADC Therapeutics in a research note on Friday, March 7th. Finally, Guggenheim dropped their price target on shares of ADC Therapeutics from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, ADC Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $7.75.

ADC Therapeutics Trading Down 7.1 %

ADC Therapeutics stock opened at $1.24 on Thursday. The stock has a 50 day moving average of $1.63 and a two-hundred day moving average of $2.22. ADC Therapeutics has a twelve month low of $1.22 and a twelve month high of $5.38. The stock has a market capitalization of $119.41 million, a price-to-earnings ratio of -0.52 and a beta of 1.51.

ADC Therapeutics (NYSE:ADCT) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.06. The company had revenue of $19.00 million for the quarter, compared to analysts’ expectations of $19.01 million.

Institutional Investors Weigh In On ADC Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ADCT. Redmile Group LLC grew its stake in shares of ADC Therapeutics by 2.6% during the 3rd quarter. Redmile Group LLC now owns 15,669,217 shares of the company’s stock worth $49,358,000 after purchasing an additional 400,000 shares during the period. JPMorgan Chase & Co. boosted its holdings in ADC Therapeutics by 164.1% during the third quarter. JPMorgan Chase & Co. now owns 78,813 shares of the company’s stock worth $248,000 after buying an additional 48,976 shares in the last quarter. Platinum Investment Management Ltd. grew its position in ADC Therapeutics by 11.6% during the fourth quarter. Platinum Investment Management Ltd. now owns 1,612,556 shares of the company’s stock worth $3,209,000 after buying an additional 168,040 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in ADC Therapeutics by 10.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 194,258 shares of the company’s stock valued at $612,000 after buying an additional 18,796 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of ADC Therapeutics by 15.6% during the 3rd quarter. Geode Capital Management LLC now owns 953,171 shares of the company’s stock valued at $3,002,000 after acquiring an additional 128,454 shares during the period. Institutional investors and hedge funds own 41.10% of the company’s stock.

ADC Therapeutics Company Profile

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.